Devlin Jodi 4

What Happened
Jodi Devlin, Chief of Clinical Operations at TriSalus Life Sciences (TLSI), reported three open-market/private sales totaling 3,207 shares for aggregate proceeds of approximately $13,171. The sales were: 1,162 shares at $4.13 ($4,799) on 2026-03-11; 1,772 shares at $4.09 ($7,247) on 2026-03-12; and 273 shares at $4.12 ($1,125) on 2026-03-16. Per the filing footnote, these disposals represent shares sold to satisfy tax withholding on vested restricted stock units (RSUs) and are not discretionary sales.

Key Details

• Transaction dates and prices:
  • 2026-03-11: 1,162 shares sold @ $4.13 = $4,799
  • 2026-03-12: 1,772 shares sold @ $4.09 = $7,247
  • 2026-03-16: 273 shares sold @ $4.12 = $1,125
• Total shares sold: 3,207; total proceeds: ~$13,171
• Footnote: F1 — Shares sold to satisfy tax withholding on vested RSUs; not a discretionary sale (transaction code F / S).
• Shares owned after the transactions: not provided in the supplied filing excerpt.
• Filing timeliness: Form 4 was filed on 2026-03-20; this appears to be after the standard two-business-day reporting window for the reported transactions, indicating a late filing.

Context
Sales to cover tax withholding on vested awards are common and generally considered administrative in nature rather than a directional bet on the stock. This filing documents routine tax-related disposals rather than a market-timed sale by the insider.